Hepatitis C genotype 1 infection in HIV–Infected patients in the era of direct-acting antiviral therapy

Authors


  • Financial support for this study came from the National Institute on Drug Abuse (grants K24DA034621 and R01DA16065) and from the National Center for Research Resources (grant UL1RR025005), which is a component of the National Institutes of Health and the National Institutes of Health Roadmap for Medical Research.

  • Potential conflict of interest: Mark S. Sulkowski received consulting fees and research grants (via Johns Hopkins University) from Abbott Laboratories, Bristol-Myers Squibb, Boehringer Ingelheim Pharmaceuticals, Gilead, Janssen, Merck, Roche/Genentech, and Vertex.

Abstract

Watch the interview with the author

Watch a video presentation of this article

Answer questions and earn CME

Ancillary